Drug Approval | December 28, 2021
Sun Pharma receives DCGI approval for Molxvir in India
The product is expected to be available in a week’s time
The product is expected to be available in a week’s time
DCGI approved the drug based on the review of clinical data
The drug will be marketed under the brand name Molnaflu
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
The capsules are the generic version of the reference listed drug Mycobutin
Subscribe To Our Newsletter & Stay Updated
